First Trust Advisors LP Purchases 193,254 Shares of Insmed, Inc. $INSM

First Trust Advisors LP boosted its position in shares of Insmed, Inc. (NASDAQ:INSM) by 407.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 240,646 shares of the biopharmaceutical company’s stock after buying an additional 193,254 shares during the period. First Trust Advisors LP owned approximately 0.11% of Insmed worth $34,655,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Stone House Investment Management LLC bought a new stake in shares of Insmed during the 3rd quarter worth approximately $29,000. SBI Securities Co. Ltd. increased its stake in Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in Insmed by 59.6% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 81 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 151 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in Insmed by 109.5% during the third quarter. AlphaQuest LLC now owns 287 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 150 shares during the last quarter.

Insider Activity

In other news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the sale, the insider directly owned 41,754 shares in the company, valued at approximately $7,315,300.80. The trade was a 67.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO William Lewis sold 19,215 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00. Following the completion of the transaction, the chief executive officer directly owned 306,891 shares of the company’s stock, valued at $51,864,579. This represents a 5.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 189,651 shares of company stock valued at $31,784,545 over the last quarter. Corporate insiders own 3.00% of the company’s stock.

Insmed Stock Performance

NASDAQ INSM opened at $139.52 on Friday. The firm’s fifty day moving average price is $155.93 and its two-hundred day moving average price is $165.62. The stock has a market cap of $30.07 billion, a PE ratio of -21.77 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm’s revenue was up 152.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.32) earnings per share. On average, equities analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on INSM. Roth Mkm raised Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Wells Fargo & Company dropped their price objective on Insmed from $234.00 to $208.00 and set an “overweight” rating for the company in a research report on Friday, February 20th. Cantor Fitzgerald raised their price objective on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Guggenheim decreased their target price on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Finally, Truist Financial set a $205.00 target price on Insmed in a research report on Monday, January 12th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $207.52.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.